Investigators have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy with immune checkpoint inhibitors. Their findings, published by You et al in the Journal of the National Cancer Institute, implicate DDR1- and DDR2-driven signature scores in predicting the response to these agents and might help guide clinicians to the most effective treatments for patients in this setting.
“Our work indicates that these genetic signatures may prove to be tremendously valuable in predicting immunotherapy response in patients with bladder cancer, but also other tumor types,” said Dan Theodorescu, MD, PhD, Director of Cedars-Sinai Cancer, the Phase One Foundation Distinguished Chair, and senior author of the study. “We will continue investigating these biomarkers with the goal of bringing them into clinical use and improving patient outcomes.”
During the past 5 years, anti–PD-1/PD-L1 therapy has proved effective against many cancer types, according to Keith Syson Chan, PhD, a translational scientist, Professor of Pathology and coauthor of the study.
“It has proven very effective against melanoma and revolutionized lung cancer treatment,” Dr. Chan said. “Bladder cancer is considered one of the more responsive tumor types, but still has just a 25% durable response rate, so improvement is still needed.”
When a tumor causes a host immune reaction, immune cells usually are able to infiltrate the core of the tumor, which is deemed a “hot” tumor. Some tumors, on the other hand, block immune cells from infiltrating and are known as “cold” tumors.
A previous study by Dr. Theodorescu implicated the gene DDR2 (discoidin domain receptor tyrosine kinase 2) in contributing to anti–PD-1 resistance in animal models in several tumor types. In a collaboration between cancer biologists and bioinformatics researchers, this new study further investigated the DDR gene family using human cancer data sets in various tumor types.
Sungyong You, PhD, a computational biologist with expertise in urologic oncology and first author of the study, analyzed data from The Cancer Genome Atlas program to look at how expression of DDR2 and the related gene DDR1 correlated with the host immune response to a tumor, using bladder cancer as a model. He also looked at how genes regulated by DDR2 and DDR1 (ie, gene signatures) correlated. He then looked at patient data from IMvigor 210, a clinical trial that evaluated immunotherapy response in bladder cancer, to see if these responses correlated with DDR2 and DDR1 expression or their related gene signatures.
The investigators came away with two key findings:
“We found that these gene signatures were clearly associated with response to immunotherapy in bladder cancer and lung cancer tumors in multiple patient groups,” Dr. You said. “We also evaluated the signatures in publicly available data on melanoma, glioblastoma, and blood cancers, with similar results.”
“The next step is to validate these signatures in a prospective clinical trial,” said Dr. Theodorescu. “This could yield new tools that allow clinicians to determine pretreatment whether given patients will likely respond to anti–PD-1/PD-L1 therapy. They can then proceed with anti–PD-1/PD-L1 therapy for those patients who will derive the most benefit, and offer alternative therapies for patients not likely to respond, improving outcomes for all.”
Disclosure: The study was supported by National Institutes of Health grant numbers CA075115 and CA175397. For full disclosures of the study authors, visit academic.oup.com.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.